The newly developed Medicines Optimisation Assessment (MOAT) tool has potential to predict those patients most at risk of moderate or severe preventable ‘medication-related problems’ a recently published study has found. The authors have stated that these problems are experienced by 41% of admissions.
For some years now the concept of medicines optimisation has been one that hospital pharmacists have been involved in. This study sought to develop a prediction tool to target patients most in need of pharmacists’ input in hospital.
Eighteen risk factors were preselected for MOAT development, with 11 variables retained in the final model. The MOAT demonstrated fair predictive performance and good calibration.
Decision curve analysis suggested that the MOAT has potential value in clinical practice in guiding decision-making.
The authors have said that external validation is now required to establish predictive accuracy in a new group of patients.
An author on the study Cathy Geeson commented:
“Our motivation for the study was to increase the efficiency of hospital clinical pharmacy services while maintaining patient safety. We believe the MOAT has the potential to permit pharmacists to focus on where they are likely to have the greatest impact, thereby supporting delivery of national targets related to safety, medicines optimisation and service provision.”
We are delighted that author Cathy Geeson will join us on the PIP podcast in the coming weeks to share further details about the study.